Table 2.
Frequency of various articular and extra-articular manifestations, treatment regimens and laboratory abnormalities in 105 patients
| No. | % | |
|---|---|---|
| Current Treatment | ||
| Methotrexate | 53 | 50.5 |
| Sulphasalazine | 28 | 26.7 |
| Leflunomide | 4 | 3.8 |
| Ciclosporin | 1 | 1 |
| Anti-TNF | 21 | 20 |
| Secukinumab | 13 | 12.4 |
| Ustekinumab | 7 | 6.7 |
| Bone erosions on radiography | 39 | 73.1 |
| ESR mm/hour (Means ± SD) | 32.3 | ± 25 |
| CRP mg/L (Means ± SD) | 10.5 | ± 22 |
| Nail psoriasis | 57 | 54.3 |
| Monoarthritis | 2 | 1.9 |
| Oligoyarthritis | 9 | 8.6 |
| Polyarthritis | 84 | 80 |
| Axial | 37 | 35.2 |
| Enthesitis | 27 | 25.7 |
| Dactylitis | 31 | 29.5 |
| HLA-B27 | ||
| Not available | 75 | 71.4 |
| Positive | 26 | 24.8 |
| Negative | 4 | 3.8 |
| Extra-articular | ||
| Psoriasis | 95 | 90.5 |
| IBD & psoriasis | 3 | 2.9 |
| Uveitis & psoriasis | 3 | 2.9 |
| DAPSA (Means ± SD) | 32.9 | ± 32.7 |
| PsAID-12 (Means ± SD) | 4.55 | ± 2.4 |
| HAQ (Means ± SD) | 0.86 | ± 0.62 |
| PHQ-4 | 4.04 | ± 3.0 |
| FiRST suggestive of fibromylagia | 31 | 29.5 |
ESR: Erythrocytes sedimentation rate, mm/hour: millimeters per hour, CRP: C-reactive protein, mg/L: milligrams per liter, IBD: Inflammatory bowel disease, DAPSA: Disease activity in psoriatic arthritis, PsAID-12: 12 item psoriatic Arthritis Impact of Disease Questionnaire, HAQ: Health assessment questionnaire, PHQ-4: Patient health questionnaire, FiRST: Fibromyalgia rapid screening tool